Century Therapeutics (NASDAQ:IPSC Get Rating) is one of 262 publicly-traded companies in the Biological products, except diagnostic industry, but how does it compare to its rivals? We will compare Century Therapeutics to similar companies based on the strength of its dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares Century Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current ratings and price targets for Century Therapeutics and its rivals, as reported by MarketBeat.

Century Therapeutics presently has a consensus target price of $31.00, indicating a potential upside of 260.05%. As a group, Biological products, except diagnostic companies have a potential upside of 122.93%. Given Century Therapeutics stronger consensus rating and higher probable upside, equities analysts clearly believe Century Therapeutics is more favorable than its rivals.

Profitability

This table compares Century Therapeutics and its rivals net margins, return on equity and return on assets.

Insider and Institutional Ownership

57.5% of Century Therapeutics shares are held by institutional investors. Comparatively, 53.1% of shares of all Biological products, except diagnostic companies are held by institutional investors. 16.1% of shares of all Biological products, except diagnostic companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Century Therapeutics beats its rivals on 7 of the 12 factors compared.

Century Therapeutics Company Profile (Get Rating)

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Century Therapeutics (IPSC) vs. Its Competitors Head-To-Head Analysis - Defense World